Research Papers:
RA and ω-3 PUFA co-treatment activates autophagy in cancer cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1939 views | HTML 2425 views | ?
Abstract
Shenglong Zhu1,2,3, Guangxiao Lin1,2, Ci Song1,2, Yikuan Wu1,2, Ninghan Feng3,7, Wei Chen1,2,4,5, Zhao He1,2,3 and Yong Q. Chen1,2,3,4,6
1State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China
2School of Food Science and Technology, Jiangnan University, Wuxi, China
3Wuxi Medical School, Jiangnan University, Wuxi, China
4National Engineer Research Center for Functional Food, Jiangnan University, Wuxi, China
5Beijing Innovation Center of Food Nutrition and Human Health, Beijing Technology and Business University, Beijing, China
6School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA
7Wuxi No. 2 Hospital, Jiangsu, P. R. China
Correspondence to:
Zhao He, email: [email protected]
Yong Q. Chen, email: [email protected]
Keywords: retinoic acid; ω-3 PUFAs; autophagy; breast cancer
Received: April 26, 2017 Accepted: September 21, 2017 Published: November 22, 2017
ABSTRACT
Retinoic acid (RA), is a promising therapeutic agent for the treatment of breast cancer. However, metabolic disorders and drug resistance reduce the efficacy of RA. In this study, we found that RA and ω-3 polyunsaturated fatty acids (ω-3 PUFAs) synergistically induced cell death in vitro and in vivo and autophagy activation. Moreover, RA-induced hypercholesterolemia was completely corrected by ω-3 PUFA supplementation. In addition, we demonstrated that the effects of this combination on the autophagic flux were independent of the two major canonic regulatory complexes controlling autophagic vesicle formation. The treatment activated Gαq-p38 MAPK signaling pathways, which resulted in autophagy of breast cancer cells. Knockdown of Gαq or P38 expression prevented RA and ω-3 PUFAs from inducing autophagy. Data indicated that Gαq-p38activation was mediated by the co-activation of GPR40 and RARα in lipid rafts, rather than by the activation of GPR120, RARβ, or RARγ. The results of this study suggest that hyperlipidemic drug side effects may be ameliorated by the administration of ω-3 PUFAs. Thus, the therapeutic indexes of the corresponding drugs may be increased.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22629